Carl Icahn says new Illumina CEO has his ‘full support’ months after proxy fight

Carl Icahn says new Illumina CEO has his ‘full support’ months after proxy fight


Carl Icahn speaking at Delivering Alpha in New York on Sept. 13, 2016.

David A. Grogan | CNBC

Carl Icahn on Thursday expressed his support for Illumina‘s new CEO Jacob Thaysen – a relief for the company as it tries to rebound from a bitter proxy fight with the billionaire activist investor. 

“I think he will do an excellent job and he has my full support,” Icahn said in a post on X, noting that he spoke with Thaysen. 

Icahn, who continues to own a small stake in Illumina, launched a proxy battle over the company’s decision to close its $7.1 billion acquisition of cancer test developer Grail in 2021 without approval from antitrust regulators in U.S. and European Union. 

Icahn was a staunch critic of Illumina’s former CEO Francis deSouza, who ultimately resigned after the proxy battle in May despite securing enough votes to stay. 

“I’d find it comical, if it wasn’t so reprehensible that ILMN’s share price is down 63% due to CEO Francis deSouza making such an absurd and questionable purchase,” Icahn said in a statement to CNBC in March.

Jacob Thaysen

Source: Illumina

Shares of Illumina are now down nearly 70% since closing the Grail deal in August 2021. The company’s market value has fallen to roughly $25 billion from around $75 billion in August 2021.

Investors will be watching to see how Thaysen approaches the Grail business, and whether he can rebuild the market value the company lost.

Thaysen will step in as Illumina’s CEO on Sept. 25 after nearly a decade at medical devices firm Agilent Technologies, where he ran its largest analytical-lab unit, and doubled the division’s operating profit.





Source

We’re buying the dip in a health and life sciences stock that has gone down enough
Health

We’re buying the dip in a health and life sciences stock that has gone down enough

We’re buying 20 more shares of Danaher at roughly $180 each. Following Thursday’s trade, Jim Cramer’s Charitable Trust will own 470 shares of DHR, increasing its weighting to about 2.31% from about 2.22%. While Danaher has certainly been one of a handful of problematic stocks in the portfolio, we are stepping into the name here, […]

Read More
Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial
Health

Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial

The Roche Holding AG headquarters on April 11, 2025, in Basel, Switzerland. Sedat Suna | Getty Images News | Getty Images Swiss pharmaceutical firm Roche is targeting becoming a top three obesity player globally, posing a potential rival to heavyweights Novo Nordisk and Eli Lilly as it advances one of its experimental weight-loss drugs to […]

Read More
Eli Lilly to build .5 billion Texas manufacturing facility for obesity pill, other drugs
Health

Eli Lilly to build $6.5 billion Texas manufacturing facility for obesity pill, other drugs

A rendering of Eli Lilly’s manufacturing facility in Houston, Texas. Courtesy: Eli Lilly Eli Lilly on Tuesday said it will spend $6.5 billion to build a manufacturing facility in Houston, Texas, to boost production of the company’s pipeline of so-called small molecule drugs, including its closely watched experimental obesity pill.  It is the second in […]

Read More